Cadmus Rich
Direktor/Vorstandsmitglied bei Sustained Nano Systems LLC
Vermögen: - $ am 30.04.2024
Aktive Positionen von Cadmus Rich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Cadmus Rich
Ehemalige bekannte Positionen von Cadmus Rich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AURA BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2017 | 16.10.2023 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2015 | 01.09.2017 |
North Carolina Specialty Hospital LLC | Direktor/Vorstandsmitglied | - | - |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Direktor/Vorstandsmitglied | - | - |
Treasurer | - | - |
Ausbildung von Cadmus Rich
Case Western Reserve University | Undergraduate Degree |
Regis University | Masters Business Admin |
UNC School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Operativ
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
North Carolina Specialty Hospital LLC | |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Commercial Services |
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Commercial Services |
- Börse
- Insiders
- Cadmus Rich
- Erfahrung